Trial Profile
A Prospective, Open-Label Study Comparing The Cardiac Safety Of The First Dose Of Fingolimod (FTY-Gilenya) Versus Generic Version Of Fingolimod (FTY-Generic) In Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2017
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 10 May 2017 New trial record
- 28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology.